Human bone marrow-derived (B type) lymphocytes have receptors for
with human, rabbit, or mouse C3. To demonstrate membrane-bound Ig (MBIg) on human lymphoid cells, a direct fluorescence technique was employed in which 50 #l of lymphoid cell suspension (5 × 108 cells) were incubated (4°C, 30 min) with 25 #l of FITC antihuman Ig serum. To demonstrate binding of AHG to human lymphoblastoid cells, both direct and indirect techniques were employed. In the direct method, 5 × 108 cells in 50 t~l MEM were incubated (37°C, 30 min) with 25 #l of FITC AHG. In the indirect method, cells were first incubated (37°C, 30 min) with FITC AHG, washed three times with MEM, and then reacted (4°C, 30 min), so as to cross-link FITC AHG molecules possibly bound to cells, with nonconjugated rabbit antihuman IgG serum. Before use the FITC AHG was centrifuged at 1,500 g for 20 rain in order to remove large aggregates. In the final step, cells were washed three times with MEM and resuspended in 10 ttl of 10% bovine serum albumin (BSA) in PBS. Cell smears were air dried, fixed in 95% cold ethanol, and mounted under glycerogel. Wet preparations were made by sealing a drop of the cell suspension with paramount under a cover slip. Smears were observed by using a Zeiss interference filter system utilizing transmitted light from a HBO 200 watt mercury light source. Since all cells in a given preparation stained to the same degree, we could semiquantitatively classify the intensity of stain from negative to 3+ for both surface immunoglobulin and aggregate binding.
Erythrocyte-Antibody Complement Complexes. EAC1423b hu cells were prepared from sheep
erythrocytes (E) (1 × 109 cells/ml) sensitized with rabbit antierythrocyte antibody (A), and incubated with purified human complement (C) components as previously described (14) . EAC1423b hu were stored at a concentration of 1 × 109 cells/ml GVB (Veronal-buffered saline containing 1.0% gelatin, 1.5 × 10 ' M CaCl2 and 5 x 10 _4 M MgC12). EAC1-3 mo and EAC1-5 rab cells were prepared by incubating (37°C, 30 rain) sensitized sheep erythrocytes (5 × l0 s cells) in 1 ml mouse serum diluted 1 : 5 with GVB or rabbit serum diluted 1 : 2 with GVB. Cells were washed three times and stored in GVB (1 × 109 cells/ml). The mouse serum was obtained from B10D2 old line mice (Jackson Laboratories, Bar Harbor, Maine) genetically deficient in C5 (15) . The rabbit serum was obtained from C6-deficient rabbits (16) . Each batch of EAC' cells could be used over a period of 7 days.
EAC1423d hu cells were obtained by incubating (37°C, 120 min) 5 × 107 EAC 1423b hu with a sufficient amount of C3b inactivator ~ (C3bina) or heat-inactivated (56°C, 30 rain) human serum to make them immune adherence negative. C3bina cleaves C3b into C3c and C3d and treatment of EAC1423b hu with C3bina results in release of C3c and retention of C3d on the red cell surf'ace (17) . EAC1423d hu are immune adherence negative.
Rosette Formation of Cells Bearing Receptors for Complement with EAC'. 2 x 108 lymphoblas-
told cells were incubated in small plastic Eppendorf conical tubes (Brinkman Instrument Co., Los Angeles, Calif.) with 5 × 107 EAC' in a total vol of 200 #l of MEM without Ca ++, at 37°C for 30 min, during which time the mixture was shaken twice by hand. Thereafter, the cells were suspended in 1 ml MEM and placed on ice for 5 min. Rosetted (four or more bound erythrocytes) and unrosetted lymphocytes were counted in a hematocytometer, using a Zeiss phase-contrast microscope, and the percent of rosette-forming cells was calculated.
Rosette Formation with Sheep Erythrocytes. The method of Jondal et al. (18) , with the modification of Bentwich et al. (19) was employed. In preliminary experiments it was found that approximately 60% of human peripheral lymphocytes (average of 15 experiments) formed rosettes. None of the human lymphoblastoid cell lines studied here formed spontaneous rosettes with sheep erythrocytes.
Immune Adherence. Immune adherence experiments were performed in microtiter plates (Cooke Engineering Co., Alexandria, Va.). In a typical experiment, each well was filled with 25 ~1 of Veronal buffer, pH 7.5, T/20.1, containing 0.1% human serum albumin (HSA). 25 ~l of 1 × 10 ~ EAC/ml were placed in the first well and dilutions were made with a 25 ul microtiter loop. After addition of 25 ul of human O group red cell suspension containing 2 x 108 red cells per ml to all wells, the plates were agitated for 5 rain and then incubated at 37°C for 30 min, after which time the sedimentation pattern was evaluated.
Trypsin Treatment. 5 × 106 cells were incubated with 0.01% trypsin in MEM (wt/vol) for 15 min at 37°C and then washed twice with 0.1% soy bean trypsin inhibitor in MEM. (14) . Since certain cells formed rosettes with both EAC1423b and EAC1423d, the possibility of the receptors for C3b and C3d (14) . Therefore, receptors for C3-C3b on lymphoid cells can be shown by staining cell bound C3 or C3b with FITC anti-C3 serum or by rosette formation with EAC1423b hu. The requirements for rosette formation and binding of soluble C3 and C3b may be different, resulting in different sensitivities of the two methods. Since certain cell lines did not form rosettes with EAC1423b, we investigated whether these cells were able to bind soluble C3 or C3b. Thus, the ability of the nine human cell lines to bind soluble C3 and C3b was compared to their ability to form rosettes with C3b carrying sensitized red cells, i.e., EAC1423b hu and EACI-5 rab. EACI-5 rab, although prepared with C6-deficient rabbit serum, carry C3b as demonstrated by positive immune adherence reactions with human group O erythrocytes. The results summarized in Table IV indicate that with most cell lines (Raji, SCRF5001, SCRF5004, SCRF5005, S o m m e r 8402) there was good correlation between their ability to bind soluble C3 and C3b and their ability to form rosettes with EAC1423b hu and E A C I -5 rab. However, with certain cell lines (Daudi, 8866, Wil2WT) the detection of receptors for C3-C3b by immunofluorescence was more sensitive t h a n by the rosette technique. For example, Daudi cells bound soluble h u m a n C3 and C3b as well as rabbit C3 but were unable to form rosettes with EAC1423b hu or E A C I -5 rab; 8866 and Wil2WT cells bound soluble C3 from rabbit serum but did not form rosettes with EAC1-5 rab.
Results

Membrane
The discrepancy between the results obtained for binding soluble C3-C3b and for binding red cell-bound C3b to certain cells m a y be explained by a different distribution of receptors on the cell membrane. In effect, distribution of the C3-C3b receptors on Raji and other cell lines able to form rosettes with C3b carrying red cells different than the distribution on Daudi cells unable to form rosettes with C3b carrying red cells was observed by immunofluorescence. As shown in Fig. 1 , Raji cells carrying C3 or C3b and stained with FITC a n t i h u m a n C3 showed a uniform, fine granular staining pattern whereas Daudi cells carrying C3 or C3b showed a reticulated distribution of the stain on the cell surface.
Species Specificity of the C3-C3b Receptor on Human Lymphoblastoid
Cells. In the preceding paragraph it was shown that 8866 and Wil2WT cells bound rabbit C3 but not h u m a n C3 whereas other cell lines bound C3 of both species, which indicated differences in specificity of C3-C3b receptors. In the following experiment, the species specificity of the C3-C3b receptor on h u m a n lymphoblastoid cells was analyzed by using C3 of different species. Cells were incubated with isolated h u m a n C3 and C3b as well as human, mouse, rabbit, and guinea pig sera as sources of C3 of the different species. Daudi  90  85  90  100  100  85  8866  5  5  5  80  83  90  Wi|2WT  2 3  2  2-3  70  65  70  SCRF5001  100  100  100  95  100  100  SCRF5004  100  100  100  100  92  90  SCRF5005  100  100  100  100  90  100  Raji  100  100  100  100  100  95  Sommer 8432  100  100  100  100  100  70  Sommer results showed that C3-C3b receptors on the lymphoblastoid cells tested have different species specificities.
Identification of Receptors for IgG Fc and Receptors for C3-C3b and C3d.
Since AHG as well as C3, C3b, and C3d all bound to certain cell types, we questioned whether receptor sites for IgG Fc were identical to either of the two receptors for complement, i.e., the receptors for C3-C3b or C3d. That the receptors for IgG Fc and the receptors for complement are different was shown by inhibition experiments. As shown in (Fig. 2 ) that the uptake of AHG containing complement was approximately eight times higher than that of AHG without complement. The fact the AHG containing complement bound to Raji cells only via the receptors for complement was also demonstrated in experiments in which the receptors for complement were removed from the cells by trypsin treatment. We showed previously that trypsin destroys the receptors for C3-C3b on Raji cells (14) . In the present study it was found that trypsin also destroys the receptors for C3d on Raji cells since trypsin-treated Raji cells were unable to form rosettes with EAC1423d hu or EAC1-3 too. However, the receptors for IgG Fc on Raji cells were resistant to trypsin since treated cells were still able to bind AHG. Utilizing trypsin-treated and untreated cells we were able to assess the contribution of the receptors for IgG Fc and complement to the binding of immune complexes to cells. As shown in Table VII 
Contribution of Receptors for Complement and IgG Fc to Binding of AHG
Contribution of the Receptors for C3-C3b and C3d to the Binding of AHG-Containing Complement to Cells.
In the preceding section we demonstrated that AHG in fresh serum binds to cells only via the receptors for complement. However, since Raji cells have both receptors for C3-C3b and C3d and immune complexes incubated with whole serum may contain C3b, C3d, or both C3 fragments, experiments were carried out in order to define which of the two receptors fbr complement is operative in the binding of immune complexes to the cells. In these experiments 12~I-labeled AHG and F1TC AHG were employed. Different batches of 2. (Fig. 3) . Similar results were obtained when FITC AHG-containing complement was used; these aggregates also bound to cells with blocked receptors for C3-C3b. Thus, when cells were incubated with isolated human C3, C3b, or human serum and then reacted with FITC AHG which had previously interacted with whole human serum, fluorescence staining of the cells was observed. The results showed that AHG-containing complement binds to cells via both receptors for C3-C3b and C3d. from the cells by 100 ttl of whole fresh NHS containing 150 tLg C3. As is shown also in Fig. 4 , when 100 t~l of a solution containing 150 pg human C3 or C3b was added to [125I]AHG-coated cells, approximately 41% and 34% of the bound AHG was released, respectively. The percent of released radioactivity was decreased proportionately with the amount of serum, C3 or C3b used. The results indicate that NHS and purified human C3 or C3b can release some AHG containing complement bound to Raji cells.
Release of AHG-Containing
Discussion
In the present work, we studied MBIg and receptors for IgG Fc and complement of nine different human lymphoblastoid cell lines having B-type cell characteristics. Some of the cell lines studied expressed all of the described B-type lymphocyte markers (MBIg, receptors for IgG Fc, receptors for complement). However, other cell lines showed only some of these markers. For example: we found cell lines without MBIg but with receptors for IgG Fc and complement, cell lines with MBIg and receptors for complement but without receptors for IgG Fc, and cell lines without MBIg and receptors for IgG Fc but with receptors for complement. The data suggest that cell lines lacking certain B-cell markers may be derived from B cells which did not express all the surface markers, such as B cells at different stages of maturation or B cells belonging to different subclasses. On the other hand, cultured cells may have lost surface receptors which were present on the cells from which they were derived. For example, it has been shown that three subclasses of B-type lymphocytes are present in the blood of patients with chronic lymphocytic leukemia; cells having only MBIg, cells having only receptors for C3 and cells having both MBIg and receptors for C3 (24) . In addition, in patients with X-linked agammaglobulinemia, lymphocytes without MBIg but with receptors for C3 have been described (25) . Furthermore, loss of MBIg has been reported to occur in cultured cells (26) .
Dickler et al. (27) Two types of receptors for complement were found to be present on the cell lines tested, one for C3 and C3b and one for C3d. Using sensitized red cells carrying C3b or C3d, it was found that some cell lines have both receptors for C3b and C3d, while others have only receptors for C3d, and others have neither receptor. By using the rosette test, it was shown that all cell lines having receptors for C3b also had receptors for C3d. Similar results with other cell lines have been reported by Ross et al. (3) and Dierich et al. (28) .
In addition to the rosette test, the more sensitive fluorescent technique was used for detecting C3-C3b receptors on cells. By employing this technique it was found that cell lines unable to form rosettes with EAC1423b hu and EACI-5 rab bound soluble C3 and C3b. Sommer 8402 is the only cell line of those tested which did not reveal a C3-C3b receptor by either method. Since this cell line formed rosettes with EAC1423d hu and EAC1-3 mo, we concluded that it has only the C3d receptor.
The different sensitivities of the immunofluorescence and the rosette techniques in demonstrating C3-C3b receptors may be due to the fact that EAC' is a large particle and in order to attach to cells it may require a special arrangement as well as a large number of C3-C3b receptors on the surface of the lymphoid cells. In fact, a difference in the distribution of the receptors for C3-C3b was observed by immunofluorescence between cells able to form rosettes with EAC1423b h~ and EAC1-5 rab, and cells (Daudi) which were unable to form rosettes with EAC1423b h~ and EACI-5 rab. That the rosette technique does not always detect C3-C3b receptors on the cell surface is also supported by the demonstration of Dierich (personal communication), who found C3 receptor activity in solubilized cell extracts from lymphoid cell types which do not form rosettes with EAC1423b hu. Moreover, Nelson and Uhlenbruck (29) found that mucoids derived from bovine erythrocytes inhibited the interaction of EAC1423b hu with human erythrocytes which carry C3b receptors, whereas no interaction was observed with bovine red cells by themselves and EAC1423b hu.
In several reports on the classification of peripheral human lymphocytes as T and B cells, it has been stated that the percentage of' B cells having MBIg was higher than that of B cells having C3b receptors (24, 30, 31) . In those studies, C3b receptors were demonstrated by the rosette technique. Since the fluorescence method is more sensitive in detecting C3b receptors than the rosette technique, it may reveal a percentage of C3b receptor-bearing cells similar to that of Ig-bearing cells. We had already {ound that approximately 20% of human peripheral lymphocytes bound soluble C3b (14) .
We have previously shown that the receptors for C3 and C3b are identical (14) . In the present study we demonstrated that the receptors for C3-C3b are distinct from the receptors fbr C3d. Other experimental data also support the concept that C3-C3b and C3d receptors are independent. Ross et al. have shown that human red cells have only C3b receptors (3). The same authors used antisera to C3b and C3d receptors to show that the two receptors are distinct on the surface of human peripheral lymphocytes and cells of lymphoid cell lines (3) .
A broad spectrum of species specificity of C3-C3b receptors on the human lymphoblastoid cell lines studied was shown by using C3 of different species. Whereas the majority of cell lines bound human C3 and C3b as well as mouse, rabbit, and guinea pig C3, some cell lines did not bind human C3 and C3b but were able to bind mouse, rabbit and guinea pig C3. The reason that some cell lines did not bind human C3 and C3b but bound C3 from other species is not understood. It may be that the specificity of C3 receptors of' human lymphoid cells is altered in culture.
The receptors for IgG Fc and the receptors for C3-C3b and C3d are distinct since inhibition experiments demonstrated that Raji cells with blocked receptors for IgG Fc were able to bind soluble C3 and C3b and to form rosettes with sensitized red cells carrying C3b or C3d. The possibility that the receptors fbr IgG Fc, C3-C3b, and C3d are a class of Ig is excluded by the fact that Raji cells do not carry MBIg.
The contribution of each of' the three receptors to the binding of soluble immune complexes containing complement to cell surfhces was assessed by using Raji cells which have IgG Fc, C3-C3b, and C3d receptors. It was demonstrated that the receptors for complement are far more important in binding immune complexes containing complement than receptors for Fc. In fact, it was shown that the binding of' AHG containing complement was primarily mediated via the receptors for complement, since the amount of AHG containing complement bound to cells with or without blocked receptors fbr Fc was virtually the same. In contrast, the binding of AHG without complement was almost completely inhibited when cells with blocked receptors for Fc were used. The importance of complement receptors in the binding of complexes containing complement to cells was further demonstrated by using Raji cells with and without receptors for complement. Receptors for complement, but not IgG Fc, were removed from the cells by mild trypsin treatment. When these cells were used, it was found that AHG without complement bound to Raji cells with and without complement receptors, whereas AHG containing complement bound only to complement receptor carrying Raji cells. Our findings indicate that the increased binding to cells of AHG containing complement, as compared to that of AHG without complement, is not due to additive binding via both Fc and complement receptors but is due to binding via complement receptors only. These results are in agreement with the studies of Eden, Bianco, and Nussenzweig, who have postulated that the complement mediated binding affects and impedes the Fc mediated binding of immune complexes to lymphocytes (32) . According to these authors, complement bound to the antibody within the complexes may sterically hinder or directly bind to the sites on the Ig molecules which have affinity for the lymphocyte membrane. Although soluble aggregates containing complement bind to cells primarily via complement receptors, it should be noted that in other systems it has been shown that receptors for IgG Fc play a significant role in other cell functions such as phagocytosis of EAC' (33, 34) .
In the course of complement activation, C3b binds to immune complexes. Complex-bound C3b is thereafter cleaved by the serum enzyme C3b inactivator into C3c and C3d, with the d portion remaining on the immune complex (17) . Therefore, immune complexes in whole serum may contain C3b, C3d, or both. Experiments presented here indicated that both receptors for C3-C3b and C3d are operative in binding of immune complexes coated with complement to cells. These experiments also suggested that Raji cells have approximately the same number of receptors for C3;C3b and C3d on their surface since it was found that 50% of aggregates that bound to cells with nonblocked receptors for C3-C3b could still bind to cells with blocked receptors for C3-C3b.
Miller, Saluk, and Nussenzweig showed that immune complexes containing complement bound to murine B lymphocytes could be released from the cells by addition of NHS but not by addition of isolated human C3 or C3b (23) . The authors postulated that release is due to activation of the alternate pathway of the complement system by complex-coated cells, which results in the generation of products which modify or cover the C3 binding sites on the complexes which are then released. In our experiments, NHS as well as isolated soluble human C3 and C3b could release a substantial percentage of' immune complexes bound to Raji cells via receptors fbr complement. Since in our study not only whole serum but also isolated C3 or C3b were able to release immune complexes bound to Raji cells, we postulated that release of complexes from Raji cells by human serum is due to the presence in serum of C3 or C3b. C3b could be generated by activation of complement by immune complexes at the site of binding. We have previously shown that C3 or C3b competes with the red cell-bound C3b (EAC 1423b) for receptors for C3-C3b on Raji cells because addition of C3 or C3b to Raji-EAC 1423b hu rosettes resulted in dissociation of rosettes (14) . Additional evidence of competition between free C3 and C3b and complexes containing complement for the receptors for complement has been obtained by other experiments in which uptake of AHG by Raji cells was greatly diminished when an excess of human serum was present. 3 NHS as well as C3 and C3b were unable to release more than approximately 50% of cell-bound complement-coated aggregates, which may again indicate that part of immune complexes are bound to cells via the receptors for C3d.
Summary
In the present work we studied the expression of membrane-bound Ig (MBIg) as well as receptors for IgG Fc and complement on nine human lymphoblastoid cell lines. When MBIg and receptors for IgG Fc were compared, four categories of cell lines could be distinguished: (a) cell lines having both MBIg and receptors for IgG Fc, (b) cell lines having MBIg but lacking receptors for IgG Fc, (c) cell lines lacking MBIg but having receptors for IgG Fc, and (d) cell lines lacking both MBIg and receptors for IgG Fc. Two types of receptors for complement could be detected on the cell lines studied, one for C3-C3b and one for C3d. When sensitized red cells carrying C3b or C3d were used for rosette tests, three categories of cell lines could be distinguished: (a) cell lines having receptors for C3b and C3d, (b) cell lines having receptors only fbr C3d and (c) cell lines lacking both receptors. However, when a more sensitive immunofluorescent method was used instead of the rosette technique, it was found that cell lines unable to form rosettes with EAC1423b hu were able to bind soluble C3 or C3b which indicated the presence of these receptors on the cell surface. Inhibition experiments showed that receptors for C3-C3b and receptors for C3d are distinct and that receptors for C3-C3b and C3d are different from receptors for IgG Fc.
A cell line (Raji) without MBIg but with receptors for IgG Fc, C3-C3b, and C3d was selected for use in studying the binding mechanism of soluble immune complexes to cell surface membrane. Aggregated human gamma globulin was used in place of immune complexes. Immune complexes containing complement bind to Raji cells only via receptors for complement, namely receptors for C3-C3b and C3d. Binding of immune complexes containing complement to cells is much greater than that of complexes without complement. Immune complexes bound to cells via receptors for complement can be partially released from the cell surface by addition of normal human serum as well as isolated human C3 or C3b. We postulate that such release is due to competition of immune complex bound C3b and free C3 or C3b for the receptors on Raji cells.
